🇺🇸 FDA
Patent

US 8029788

Variants of humanized anti-carcinoma MAb CC49

granted A61KA61K2039/505A61K38/00

Quick answer

US patent 8029788 (Variants of humanized anti-carcinoma MAb CC49) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Oct 04 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K38/00, A61K49/0002, A61K51/1045